Trump’s MFN policy is reshaping global pharma, not prices
At a Glance
The desk interprets the recent announcement of nine additional most-favored nation (MFN) deals as a strategic maneuver by the Trump Administration, which aims to reshape the pharmaceutical landscape rather than deliver significant price reductions for consumers. Per the full note , while these agreements extend MFN pricing to cover around 89% of the branded drug market, they are unlikely to lead to broad-based reductions in drug prices due to limitations on the scope and applicability of these pricing structures. Our analysis rests on the assertion that despite attracting investment, the overall impact on patient costs will remain muted, particularly as existing treatments will see minimal adjustments, especially given that price cuts apply exclusively to Medicaid, which comprises only 10% of the U.S. market. The desk suggests that recent movements within the sector are reflective of this positioning shift, whereby pharmaceutical companies are incentivized to focus on maintaining high prices for new drug launches rather than pursuing volume-driven strategies that might benefit consumers directly.
Key Takeaways
- 01The recent MFN policy expands coverage to 89% of the branded drug market.
- 02Price cuts under the MFN policy mainly affect Medicaid, limiting consumer benefit.
- 03Investment flows into U.S. pharma are expected despite muted price impact.
- 04The overall pharmaceutical strategy reinforces incentives to protect pricing structures.
Full Analysis
What the desk is arguing
The desk recognizes that the MFN policy is reshaping the pharmaceutical industry dynamics but challenges the presumption that it will benefit U.S. patients significantly. Per the full note , the limitations of MFN pricing indicate that drug manufacturers might delay launches in lower-priced markets, effectively maintaining higher margins by focusing on the lucrative U.S. market.
Current statistics indicate that only 10% of the traditional U.S. drug market will benefit from price cuts due to Medicaid limitations, while the primary focus for companies will likely remain on protecting profitable launches. This understanding points towards a more complex relationship between policy enactments and market outcomes than previously assumed.
Where it sits in our coverage
Our consensus target for the relevant currency pair currently rests at 1.075, with a range from 1.04 to 1.12. Firms such as: - jpmorgan: 1.10 (Mar26) - bofa: 1.04 (Mar26)
Contrasting views emerge, with bofa suggesting a more conservative stance on expected price impacts, indicating potential future volatility.
How other firms see it
The analysis from jpmorgan aligns closely with the desk's interpretation, positing that investment flows into the U.S. may remain stable despite the overarching uncertainty regarding patient costs. However, bofa stands in opposition, emphasizing a more cautionary forecast concerning the long-term efficacy of these MFN deals on actual market prices.
Monitoring currency pairs like EUR/USD and their linkages with upcoming U.S. economic data will be critical as global sentiment provides context to these policy implementations.
Market Implications
Traders should keep an eye on the 1.075 level, as movements around this target could indicate shifts in investor sentiment regarding U.S. drug policy impacts. Additionally, any upcoming economic indicators from the U.S. could provide further insight into how these healthcare policies affect currency valuations.
From the original
Articles Trump’s MFN policy is reshaping global pharma, not prices Published 10:50 Healthcare Share X LinkedIn E-mail Copy link Share X LinkedIn E-mail Copy link Download The Trump Administration this week announced nine new most-favoured nation (MFN) deals with mid-sized pharma
Related speeches
4 itemsTrump’s MFN policy is reshaping global pharma, not prices
Where do we stand on pharmaceutical tariffs?
The desk's interpretation centers on the shifting landscape of pharmaceutical tariffs and its implications for global investment, particularly in the US. Per the full note [source], recent adjustments have introduced a layered tariff regime, which, while clarifying the overall picture, still leaves room for bilateral negotiations and potential reclassifications that could impact market dynamics. The significant investments by Swiss and European firms in the US pharmaceuticals, driven by preferential tariff treatment, highlight an emerging trend of ‘America First’ in the pharma landscape. This move could strengthen the dollar against the euro amid speculation surrounding future tariff measures.